RxDoctor Payments Data

Danielle Goodell

Acute Care · Toledo, OHNPI 1841755329

Payments from drug & device makers

$2,525in general payments, 2019–2025

Across 100 payments — averaging $25.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$304
  • Takeda Pharmaceuticals U.S.A., Inc.$214
  • GSK$209
  • Daiichi Sankyo Inc.$185
  • Seagen Inc.$160
  • Amgen$153
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$2,32692%
  • Education$1998%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,525 in reported general payments places this provider in the 90th percentile of 1,101 acute care providers in Ohio.

See all acute care providers in Ohio

Medicare billing

Part B allowed, 2024
$197,253
Medicare patients
229
Services billed
12,859

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lenalidomide31$390,738
RevlimidLenalidomide22$348,576
PomalystPomalidomide14$317,720
Deferiprone (3 Times A Day)Deferiprone12$197,785
VenclextaVenetoclax14$182,408
EliquisApixaban23$33,322
XareltoRivaroxaban22$21,669
Anastrozole63$2,827
Hydroxyurea66$2,782
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen66$2,318
Fentanyl20$2,042
Morphine Sulfate ErMorphine Sulfate39$1,190
Ondansetron OdtOndansetron33$1,090
Oxycodone Hcl56$1,033
Acyclovir60$846

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$19$348,57622 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$47$317,72014 claims
PfizerEliquis$132$33,32223 claims
Johnson & JohnsonXarelto$37$21,66922 claims
Teva Pharmaceuticals USA, Inc.Acyclovir$35$84660 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,101 acute care providers in Ohio.

Other acute care in Toledo

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →